InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
2
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-21.3%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the detailed record of transactions filed by Hall Justin, 首席执行官. Director active across 1 company, notably NovaBay Pharmaceuticals, Inc.. Cumulatively, 2 reports have been published. Split: 2 buys · 0 sell. Total volume traded: €28k. Activity tracked since 6 December 2021. The latest transaction was disclosed on 14 September 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Hall Justin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报2 总计
10,000 股@ US$0.152.8% 占其流量Common StockSEC:0001437749-22-022651:0
标准退出：2022年12月13日 (T+90)
69,767 股@ US$0.4394.6% 占其流量Common StockSEC:0001437749-21-027958:0
标准退出：2022年3月6日 (T+90)
2 条申报中的 2 条
About Hall Justin
Justin Hall is the CEO, General Counsel, and Director of NovaBay Pharmaceuticals, Inc. He oversees the company's operations and ensures legal compliance. His role is essential for the company's strategy and risk management.
